Bayer sued Johnson and Johnson, alleging false advertising for its prostate cancer drug Erleada, claiming it misleads patients.

By Jonathan Stempel NEW YORK, Feb 23 (Reuters) - Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely ...

Pharmaceutical manufacturer Johnson & Johnson is expanding its operations in Pennsylvania by building a new cell therapy ...

Feb 19 (Reuters) - ⁠Johnson & ⁠Johnson ⁠is preparing a ​potential sale ‌of the ‌orthopedics ⁠unit ⁠that it has been planning ...

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...

It's about striking that perfect balance between chasing growth and protecting what you already have.

Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to ...

A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the ...

Jessica Dean, of Dallas-based Dean Omar Branham Shirley, talked to Law.com about the $1.5 billion talc verdict that jurors in Baltimore, Maryland, returned on Monday against Johnson & Johnson. The ...

Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.

Johnson & Johnson is taking flight with the New York Jets, joining the NFL team’s roster in a multiyear agreement as its official medical innovation sponsor. Under the new sponsorship, unveiled ...

Johnson & Johnson JNJ reported 6.0% sales growth and 8.1% diluted adjusted earnings per share growth in 2025, with 2026 growth guidance of 6.7% for sales and 6.9% for diluted adjusted EPS at the ...